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The purpose of this study is the assessment of gel technology based on a lauroyl
derivative of gemcitabine encapsulated in lipid nanocapsules delivered
subcutaneously or intravenously after dilution to
1. target lymph nodes,
2. induce less systemic toxicity and
3. combat mediastinal metastases from an orthotopic model of human, squamous,
non-small-cell lung cancer Ma44-3 cells implanted in severe combined
immunodeficiency mice.
The gel technology mainly targeted lymph nodes as revealed by the biodistribution
study. Moreover, the gel technology induced no significant myelosuppression
(platelet count) in comparison with the control saline group, unlike the
conventional intravenous gemcitabine hydrochloride treated group (P < 0.05).
Besides, the gel technology, delivered subcutaneously twice a week, was able to
combat locally mediastinal metastases from the orthotopic lung tumor and to
significantly delay death (P < 0.05) as was the diluted gel technology delivered
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